19 completed, 4 terminated, 1 active not recruiting, 1 withdrawn. 14 Phase 2, 10 Phase 1, 3 Not applicable, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Terminated 3, Withdrawn 1 |
| Phase 1 | 10 | Completed 7, Terminated 3 |
| Not applicable | 3 | Completed 3 |
| Early Phase 1 | 2 | Completed 2 |
Follow Contiguous Stage II Mantle Cell Lymphoma: new trials by email Literature Review of Contiguous Stage II Mantle Cell Lymphoma trials Research Report on Contiguous Stage II Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma ibrutinib, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | Northwestern University | 37 | 2015-01-12 | 2026-06-10 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 23 | 2011-10-03 | 2023-07-27 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma bortezomib, filgrastim, autologous hematopoietic stem cell transplantation - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 23 | 2011-07-01 | 2021-05-10 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
| Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma bortezomib, rituximab, cyclophosphamide - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 77 | 2007-05-01 | 2014-10-30 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies cyclophosphamide, fludarabine phosphate, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | Fred Hutchinson Cancer Center | 23 | 2006-04-01 | 2015-02-11 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
Showing 20 of 25. Sign in to see all of them.
Lymphoma, Mantle-Cell (24) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma, B-Cell, Marginal Zone (20) · Lymphoma, Follicular (20) · Lymphoma, Large B-Cell, Diffuse (20) · Burkitt Lymphoma (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Waldenstrom Macroglobulinemia (18) · Lymphoma, Non-Hodgkin (17) · Lymphoma, Large-Cell, Immunoblastic (16) · Hodgkin Disease (13) · Lymphoma, Extranodal NK-T-Cell (13) · Lymphoma, T-Cell, Cutaneous (12) · Mycosis Fungoides (12) · Sezary Syndrome (12)
Hemic and Lymphatic Diseases (25) · Immune System Diseases (25) · Immunoproliferative Disorders (25) · Lymphatic Diseases (25) · Lymphoproliferative Disorders (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Lymphoma (24) · Blood Protein Disorders (21) · Cardiovascular Diseases (21) · Chronic Disease (21) · Disease Attributes (21) · Hematologic Diseases (21) · Hemorrhagic Disorders (21) · Hemostatic Disorders (21)
Rituximab (10) · Cyclophosphamide (6) · fludarabine phosphate (6) · Mycophenolic Acid (5) · Peripheral Blood Stem Cell Transplantation (5) · Cyclosporine (4) · Tacrolimus (4) · Whole-Body Irradiation (4) · Bortezomib (3) · Etoposide (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Busulfan (2) · Carboplatin (2) · Doxorubicin (2)
National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (5) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · Northwestern University (2) · Wake Forest University Health Sciences (2) · Barbara Ann Karmanos Cancer Institute (1) · Burzynski Research Institute (1) · University of Chicago (1) · University of Nebraska (1) · University of Washington (1)
United States (25) · Italy (2) · Germany (1)
Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Ann Woolfrey (1) · Barbara Pro, MD (1) · Brad Kahl (1) · Brenda Sandmaier (1) · Brian Hill, MD (1) · Colleen Delaney (1) · David Maloney (1) · Divaya Bhutani, M.D. (1) · Janet Tooze, PhD (1) · John Byrd (1) · Lihua Budde (1) · Lode Swinnen (1)
PMID 32499241, PMID 18698002, PMID 24458437, PMID 26853648, PMID 29954415, PMID 30562587, PMID 31388792, PMID 37756532, PMID 40720747
P30CA015704 (3), P01CA018029 (2), P01CA078902 (1), P30CA014599 (1), P30CA022453 (1), P30CA036727 (1), P30CA043703 (1), P30CA046592 (1), P30CA060553 (1), R21CA119519 (1), R24HL074445 (1), R43HL106868 (1), RC2HL101844 (1), U01CA076576 (1), U01CA132194 (1)